(Q36895058)

English

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

scientific article published on 29 July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

pancreatic cancer

1 reference

based on heuristic

inferred from title

Brian M. Wolpin

11

object named as

Brian M Wolpin

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

12

object named as

Eunice L Kwak

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jeffrey W Clark

7

object named as

Jeffrey W Clark

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

4

object named as

David P Ryan

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Lawrence S Blaszkowsky

6

object named as

Lawrence S Blaszkowsky

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

10

object named as

Kimmie Ng

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

author name string

Jason E Faris

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jamie Arnott

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Hui Zheng

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Thomas A Abrams

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Peter C Enzinger

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Aram F Hezel

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

publication date

29 July 2011

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

30

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1614-1620

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670147

29 September 2017

Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670147

29 September 2017

Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670147

29 September 2017

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670147

29 September 2017

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670147

29 September 2017

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670147

29 September 2017

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670147

29 September 2017

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670147

29 September 2017

A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670147

4 September 2018

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670147

4 September 2018

Pancreatic cancer: how can we progress?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21800081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9708-3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36895058&oldid=2199517903"